NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Genome Biologics

Genome Biologics

Private
FrankfurtHealthcare & Life Scienceshttps://genomebiologics.com/

Last Round

VC Round

Dec 20, 2021

Total Funding Raised

$3.01M

Company Overview

Genome Biologics is a biotechnology company that provides human cardiac organoid services for drug discovery, cardiac safety pharmacology, and disease modeling.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Clinical Trials, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

human cardiac organoidscontract research organizationCROcardiotoxicity screeningorganoid platformdrug discovery servicescardiovascular disease modelingalternative to animal testing3D cell cultureiPSC-derived organoidsheart-in-a-dishmulti-omics profilingcardiac safety pharmacologypredictive toxicologypreclinical studiesnew approach methodologiesNAMsAI-augmented drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genome Biologics Comparables

Compare Genome Biologics with similar companies based on industry and business-model similarity.

Genome Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HeartBeat.bio AG
90%
Ncardia
83%
Dynomics
82%

Genome Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 20, 2021
GrantSep 1, 2018

Genome Biologics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 20, 2026

    Monthly visitors increased 1527% MoM.

  • Jun 1, 2025

    Monthly visitors increased 223% MoM.

Genome Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Genome Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Genome Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersFrankfurt
Employee Range3
Year Founded2016
Last FundingDec 20, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.